More on 06160

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Friends, Peers and Foes (?): BGNE, 49B, LEGN, MTEM, YI (more...)

May 7, 2021 12:00 AM China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
May 6, 2021 04:05 PM BeiGene Reports First Quarter 2021 Financial Results
Apr 28, 2021 07:17 AM BeiGene (BGNE) Announces BRUKINSA Demonstrates Superior OS Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutin
Apr 28, 2021 07:00 AM BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against
Apr 12, 2021 01:33 PM BeiGene (BGNE) Presents Interim Analysis of Phase 3 Trial of Tislelizumab in NSCLS at AACR
Apr 12, 2021 01:30 PM BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Apr 11, 2021 04:00 PM BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
Apr 8, 2021 07:03 AM BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints
Apr 8, 2021 07:00 AM BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Apr 8, 2021 07:00 AM BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
View All Articles